Listening to Prozac

LDR 04288cam a2201045 a 4500
001 002817562
003 MiAaHDL
005 20221116000000.0
006 m d
007 cr bn ---auaua
008 921027s1993 nyu b 001 0 eng
010 ⊔ ⊔ ‡a 92050733
016 7 ⊔ ‡a9411232 ‡2DNLM
019 ⊔ ⊔ ‡a28692819 ‡a59999299 ‡a319000205
020 ⊔ ⊔ ‡a9781857022841 ‡q(FOURTH ESTATE1994pbk)
020 ⊔ ⊔ ‡a185702284X ‡q(FOURTH ESTATE1994pbk)
020 ⊔ ⊔ ‡a9781857022339 ‡q(FOURTH ESTATE)
020 ⊔ ⊔ ‡a1857022335 ‡q(FOURTH ESTATE)
020 ⊔ ⊔ ‡a9780670841837
020 ⊔ ⊔ ‡a0670841838
029 1 ⊔ ‡aNZ1 ‡b91352
029 1 ⊔ ‡aNZ1 ‡b5059258
029 1 ⊔ ‡aNLM ‡b9411232
029 1 ⊔ ‡aNLGGC ‡b101162650
029 1 ⊔ ‡aGBVCP ‡b122420543
029 1 ⊔ ‡aAU@ ‡b000009735471
035 ⊔ ⊔ ‡asdr-uiuc.99356444412205899
035 ⊔ ⊔ ‡a(EXLNZ-01CARLI_NETWORK)991020272259705816
035 ⊔ ⊔ ‡a(OCoLC)27143771
035 ⊔ ⊔ ‡z(OCoLC)28692819 ‡z(OCoLC)59999299 ‡z(OCoLC)319000205
040 ⊔ ⊔ ‡aDLC ‡beng ‡cDLC ‡dVET ‡dMLX ‡dNLM ‡dLVB ‡dBAKER ‡dNLGGC ‡dBTCTA ‡dYDXCP ‡dSXC ‡dOCLCO ‡dGBVCP ‡dOCLCF ‡dUKV3G ‡dCN5O8 ‡dZJI ‡dOCLCQ ‡dALPEL ‡dOCLCO ‡dOCLCA ‡dOCLCQ ‡dTXGRD ‡dTXJAS ‡dOCLCQ ‡dFWR ‡dIL4J6 ‡dOCLCO ‡dOCLCA ‡dOCLCO
049 ⊔ ⊔ ‡aIFHA
050 0 0 ‡aRC483.5.F55 ‡bK7 1993
060 0 0 ‡aQV 77.5 ‡bK89L 1993
082 0 0 ‡a616.85/27061 ‡220
084 ⊔ ⊔ ‡a44.38 ‡2bcl
084 ⊔ ⊔ ‡a44.42 ‡2bcl
100 1 ⊔ ‡aKramer, Peter D.
245 1 0 ‡aListening to Prozac / ‡cPeter D. Kramer.
260 ⊔ ⊔ ‡aNew York, N.Y., U.S.A. : ‡bViking, ‡c1993.
300 ⊔ ⊔ ‡axix, 409 pages ; ‡c24 cm
336 ⊔ ⊔ ‡atext ‡btxt ‡2rdacontent
337 ⊔ ⊔ ‡aunmediated ‡bn ‡2rdamedia
338 ⊔ ⊔ ‡avolume ‡bnc ‡2rdacarrier
504 ⊔ ⊔ ‡aIncludes bibliographical references and index.
505 0 ⊔ ‡aMakeover -- Compulsion -- Antidepressants -- Sensitivity -- Stress -- Risk -- Formes frustes: low self-esteem -- Formes frustes: inhibition of pleasure, sluggishness of thought -- The message in the capsule.
520 ⊔ ⊔ ‡aKramer examines the implications of taking drugs to alter personality rather than effect illness, focusing on Prozac, a popular antidepressant.
538 ⊔ ⊔ ‡aMode of access: Internet.
650 ⊔ 7 ‡aPersonality disorders. ‡2sears
650 ⊔ 7 ‡aFluoxetine ‡xSocial aspects. ‡2sears
650 ⊔ 7 ‡aAntidepressants. ‡2nli
650 ⊔ 7 ‡aFluoxetine. ‡2nli
650 ⊔ 7 ‡aPersonality change. ‡2nli
650 1 7 ‡aPersoonlijkheidsontwikkeling. ‡2gtt
650 1 7 ‡aFluoxetine. ‡2gtt
650 ⊔ 7 ‡aPersonality change. ‡2fast ‡0(OCoLC)fst01058735
650 ⊔ 7 ‡aFluoxetine ‡xSocial aspects. ‡2fast ‡0(OCoLC)fst00928201
650 ⊔ 7 ‡aFluoxetine ‡xPsychotropic effects. ‡2fast ‡0(OCoLC)fst00928199
650 ⊔ 7 ‡aFluoxetine ‡xMoral and ethical aspects. ‡2fast ‡0(OCoLC)fst00928198
650 ⊔ 6 ‡aPersonnalité ‡xDéveloppement.
650 ⊔ 6 ‡aÉthique médicale.
650 ⊔ 6 ‡aPersonnalité ‡xChangement.
650 ⊔ 6 ‡aFluoxétine ‡xEffets psychotropes.
650 ⊔ 6 ‡aFluoxétine ‡xAspect social.
650 ⊔ 6 ‡aFluoxétine ‡xAspect moral.
650 ⊔ 4 ‡aFluoxetine ‡xMoral and ethical aspects.
650 ⊔ 4 ‡aFluoxetine ‡xSocial aspects.
650 ⊔ 4 ‡aFluoxetine ‡xPsychotropic effects.
650 ⊔ 4 ‡aPersonality change.
650 ⊔ 4 ‡aEthics, Medical.
650 ⊔ 4 ‡aFluoxetine.
650 2 2 ‡aPersonality Development
650 2 2 ‡aEthics, Medical
650 1 2 ‡aFluoxetine ‡xtherapeutic use
650 1 2 ‡aFluoxetine ‡xpharmacology
650 ⊔ 0 ‡aMedical ethics.
650 ⊔ 0 ‡aPersonality development.
650 ⊔ 0 ‡aPersonality change.
650 ⊔ 0 ‡aFluoxetine ‡xPsychotropic effects.
650 ⊔ 0 ‡aFluoxetine ‡xSocial aspects.
650 ⊔ 0 ‡aFluoxetine ‡xMoral and ethical aspects.
653 ⊔ 0 ‡aPersonality ‡achange
653 ⊔ 0 ‡aFluoxetine ‡aSocial ‡aaspects
653 ⊔ 0 ‡aFluoxetine ‡aPsychotropic ‡aeffects
653 ⊔ 0 ‡aFluoxetine ‡aMoral ‡aand ‡aethical ‡aaspects
CID ⊔ ⊔ ‡a002817562
DAT 0 ⊔ ‡a20220808213021.0 ‡b20221116000000.0
DAT 1 ⊔ ‡a20221117140518.0 ‡b2023-02-26T18:55:11Z
DAT 2 ⊔ ‡a2023-02-26T18:30:02Z
CAT ⊔ ⊔ ‡aSDR-UIUC ‡cuiuc ‡dALMA ‡lprepare.pl-004-008
FMT ⊔ ⊔ ‡aBK
HOL ⊔ ⊔ ‡0sdr-uiuc.99356444412205899 ‡auiug ‡bSDR ‡cUIUC ‡puiug.30112072962167 ‡sUIU ‡199356444412205899
974 ⊔ ⊔ ‡bUIU ‡cUIUC ‡d20230226 ‡sgoogle ‡uuiug.30112072962167 ‡y1993 ‡ric ‡qbib ‡tUS bib date1 >= 1930
974 ⊔ ⊔ ‡bUIU ‡cUIUC ‡d20240325 ‡sgoogle ‡uuiug.30112033221216 ‡y1993 ‡ric ‡qbib ‡tUS bib date1 >= 1930